• Return to Headlines

Lowest Projected Earnings Growth in the Biotechnology Industry Detected in Shares of Repligen Corp (RGEN, BMRN, AMGN, BIIB, MYGN)

By Nick Russo

Below are the three companies in the Biotechnology industry with the lowest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Repligen Corp ranks lowest with a projected earnings growth of 2.3%. Biomarin Pharmac is next with a projected earnings growth of 3.3%. Amgen Inc ranks third lowest with a projected earnings growth of 9.0%.

Biogen Inc follows with a projected earnings growth of 9.3%, and Myriad Genetics rounds out the bottom five with a projected earnings growth of 13.9%.

SmarTrend recommended that its subscribers protect gains by selling shares of Biomarin Pharmac on April 17th, 2019 by issuing a Downtrend alert when the shares were trading at $85.22. Since that call, shares of Biomarin Pharmac have fallen 4.9%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: lowest projected earnings growth repligen corp biomarin pharmac amgen inc biogen inc myriad genetics

Ticker(s): RGEN BMRN AMGN BIIB MYGN